Physician profile
Eva Bell
NPI 1326035890
$4,154.86
in general payments reported to CMS, 2019-2025
16 companies · $1,891 in 2025
The $1,891 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $280 · 2024: $1,984 · 2025: $1,891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,154.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $786.13 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $653.54 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $504.17 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $418.74 | 2024-2025 | Auvelity |
| Lundbeck LLC | $393.17 | 2023-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $349.30 | 2023-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $224.78 | 2023-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $212.76 | 2023-2025 | Trintellix |
| Acadia Pharmaceuticals INC | $153.51 | 2025 | Nuplazid |
| Alkermes, INC. | $138.87 | 2024 | Lybalvi, Aristada |
| Tris Pharma INC | $104.05 | 2023-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $77.52 | 2024-2025 | Cobenfy |
| Corium, LLC | $48.12 | 2024 | Azstarys |
| Abbvie INC. | $42.18 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $33.33 | 2024 | Quviviq |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14.69 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.